Production (Stage)
Lexaria Bioscience Corp.
LEXX
$0.9461
$0.00060.06%
NASDAQ
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -5.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -5.38% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | -3.97% | |||
| SG&A Expenses | -2.60% | 34.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.17% | 1.75% | |||
| Operating Income | -36.33% | -2.24% | |||
| Income Before Tax | -39.51% | -0.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -39.51% | -0.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -60.53% | 31.03% | |||
| Net Income | -39.65% | -0.35% | |||
| EBIT | -36.33% | -2.24% | |||
| EBITDA | -35.32% | -3.43% | |||
| EPS Basic | -33.70% | 4.50% | |||
| Normalized Basic EPS | -30.61% | 2.68% | |||
| EPS Diluted | -33.70% | 4.50% | |||
| Normalized Diluted EPS | -30.61% | 2.68% | |||
| Average Basic Shares Outstanding | 4.49% | 5.06% | |||
| Average Diluted Shares Outstanding | 4.49% | 5.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||